Please assess the completion status of the following clinical trial:

Trial Title: Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \> 18 years at the time of recruitment~* treatment with Elexacaftor-Tezacaftor-Ivacaftor for \> 90 days prior to enrollment~* willing to continue twice daily airway clearance for a minimum of 90 days and up to180 days if enrolled in the continuing treatment arm~* no exacerbations in the last 28 days~Exclusion Criteria:~* active smoking or vaping (tobacco, marijuana, recreational drugs)~* recent change in chronic airway clearance regimen with the last 28 days~* inability to tolerate airway clearance or intolerance to either/or hypertonic saline and Pulmozyme~* current treatment for an acute pulmonary exacerbation~* ongoing therapy for Nontuberculous Mycobacterium (NTM)~* investigational drug use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symptom driven (Type: EXPERIMENTAL): Symptom driven performance of airway clearance regimen
- Continuous (Type: ACTIVE_COMPARATOR): Continuous performance of baseline daily airway clearance regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).